PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism

CONTEXT: Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism. OBJECTIVE: This work aimed to investigate the safety, tolerability, and efficacy of daily Tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Aliya A, Rejnmark, Lars, Rubin, Mishaela, Schwarz, Peter, Vokes, Tamara, Clarke, Bart, Ahmed, Intekhab, Hofbauer, Lorenz, Marcocci, Claudio, Pagotto, Uberto, Palermo, Andrea, Eriksen, Erik, Brod, Meryl, Markova, Denka, Smith, Alden, Pihl, Susanne, Mourya, Sanchita, Karpf, David B, Shu, Aimee D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684498/
https://www.ncbi.nlm.nih.gov/pubmed/34347093
http://dx.doi.org/10.1210/clinem/dgab577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684498/
https://www.ncbi.nlm.nih.gov/pubmed/34347093
http://dx.doi.org/10.1210/clinem/dgab577

Ejemplares similares